In the ICC, two patients diagnosed with t-AML according to 2016WHO were reclassified as the same as the 2022 WHO, whereas three patients with AML-MR according to the 2022 WHO were reclassified as AML-TP53, AML-MR and AML with MR cytogenetic abnormalities in the ICC, respectively. This evidence concerns the gene TP53 and intrahepatic cholangiocarcinoma.